Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection
McCullough et al., The American Journal of Medicine, doi:10.1016/j.amjmed.2020.07.003 (Review)
McCullough et al., Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection, The American Journal of Medicine, doi:10.1016/j.amjmed.2020.07.003 (Review)
Aug 2020   Source   PDF  
  All Studies   Meta
Review of pathophysiological principles related to early outpatient treatment and therapeutic approaches including reduction of reinoculation, combination antiviral therapy, immunomodulation, antiplatelet/antithrombotic therapy, and administration of oxygen, monitoring, and telemedicine.
Proposes an algorithm based on age and comorbidities that allows for a large proportion to be monitored and treated at home during self-isolation with the aim of reducing the risks of hospitalization and death.
McCullough et al., 6 Aug 2020, peer-reviewed, 23 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: ARTICLE IN PRESS REVIEW Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection Peter A. McCullough, MD, MPH,a,b,c Ronan J. Kelly, MD,a Gaetano Ruocco, MD,d Edgar Lerma, MD,e James Tumlin, MD,f Kevin R. Wheelan, MD,a,b,c Nevin Katz, MD,g Norman E. Lepor, MD,h Kris Vijay, MD,i Harvey Carter, MD,j Bhupinder Singh, MD,k Sean P. McCullough, BS,l Brijesh K. Bhambi, MD,m Alberto Palazzuoli, MD, PhD,n Gaetano M. De Ferrari, MD, PhD,o Gregory P. Milligan, MD, MPH,a Taimur Safder, MD, MPH,a Kristen M. Tecson, PhD,b Dee Dee Wang, MD,p John E. McKinnon, MD,p William W. O’Neill, MD,p Marcus Zervos, MD,p Harvey A. Risch, MD, PhDq a Baylor University Medical Center, Dallas, Tex; bBaylor Heart and Vascular Institute, Dallas, Tex; cBaylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, Tex; dCardiology Division, Regina Montis Regalis Hospital, Mondovı, Cuneo, Italy; eChrist Advocate Medical Center, Chicago, Ill; fEmory University School of Medicine, Atlanta, Ga; gJohns Hopkins School of Medicine, Baltimore, Md; h Cedars Sinai Medical Center, Los Angeles, Calif; iAbrazo Arizona Heart Hospital, Abrazo Health System, Phoenix, Ariz; jCarter Eye Center, Dallas, Tex; kCardiorenal Society of America, Phoenix, Ariz; lUniversity of Texas McGovern Medical School, Houston, Tex; m Bakersfield Heart Hospital, Bakersfield, Calif; nUniversity of Siena, Le Scotte Hospital Viale Bracci, Siena, Italy; oUniversity of Torino, Torino, Italy; pHenry Ford Hospital, Detroit, Mich; qYale University School of Public Health, New Haven, Conn. ABSTRACT Approximately 9 months of the severe acute respiratory syndrome coronavius-2 (SARS-CoV-2 [COVID19]) spreading across the globe has led to widespread COVID-19 acute hospitalizations and death. The rapidity and highly communicable nature of the SARS-CoV-2 outbreak has hampered the design and execution of definitive randomized, controlled trials of therapy outside of the clinic or hospital. In the absence of clinical trial results, physicians must use what has been learned about the pathophysiology of SARSCoV-2 infection in determining early outpatient treatment of the illness with the aim of preventing hospitalization or death. This article outlines key pathophysiological principles that relate to the patient with early infection treated at home. Therapeutic approaches based on these principles include 1) reduction of reinoculation, 2) combination antiviral therapy, 3) immunomodulation, 4) antiplatelet/antithrombotic therapy, and 5) administration of oxygen, monitoring, and telemedicine. Future randomized trials testing the principles and agents discussed will undoubtedly refine and clarify their individual roles; however, we emphasize the immediate need for management guidance in the setting of widespread hospital resource consumption, morbidity, and mortality. Ó 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. (  The American Journal of Medicine (2020) 000:1−7 KEYWORDS: Ambulatory treatment; Anticoagulant; Anti-inflammatory; Antiviral; COVID-19; Critical care; Epidemiology; Hospitalization; Mortality; SARS-CoV-2 Funding: None. Conflicts of Interest: None. Authorship: All authors had access to the data and a role in writing this manuscript. Requests for reprints should be addressed to Peter A. McCullough, MD, MPH, Baylor Heart and Vascular Institute, 621 N. Hall..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop